Gestational Trophoblastic Tumours: An Update for 2014

被引：61
作者：
Froeling F.E.M. [1 ]
Seckl M.J. [1 ]
机构：
[1] Department of Medical Oncology, Charing Cross Gestational Trophoblastic Disease Centre, Imperial College Healthcare NHS Trust and Imperial College London, Fulham Palace Road, London
来源：
Current Oncology Reports | 2014年 / 16卷 / 11期
关键词：
Choriocarcinoma; Choriocarcinoma Trophoblastic tumours; Gestational trophoblastic disease; Gynaecologic cancers; Gynaecological cancers; Molar pregnancy; Oncology; Pregnancy-related diseases; Trophoblastic tumours;
D O I：
10.1007/s11912-014-0408-y
中图分类号：
学科分类号：
摘要：
Gestational trophoblastic disease describes a variety of pregnancy-related diseases including the premalignant conditions of a partial and complete hydatidiform mole and the malignant disorders of invasive mole, choriocarcinoma and the rare placental-site trophoblastic tumour and epithelioid trophoblastic tumour. The availability of a highly sensitive tumour marker in the form of human chorionic gonadotrophin, the chemosensitive character of the disease with effective treatment strategies and centralization of care of a rare group of diseases has resulted in excellent survival rates, which can exceed 98 %. This review gives a general overview of gestational trophoblastic disease, the most recent insights in aetiology and pathology and a summary of the different management strategies. © 2014, Springer Science+Business Media New York.
引用
收藏
页数：10
相关论文
共 47 条
  • [1] Seckl M.J., Sebire N.J., Berkowitz R.S., Gestational trophoblastic disease, Lancet, 376, 9742, pp. 717-729, (2010)
  • [2] Palmer J.R., Advances in the epidemiology of gestational trophoblastic disease, J Reprod Med, 39, pp. 155-162, (1994)
  • [3] Sebire N.J., Foskett M., Fisher R.A., Rees H., Seckl M., Newlands E., Risk of partial and complete hydatidiform molar pregnancy in relation to maternal age, BJOG, 109, 1, pp. 99-102, (2002)
  • [4] Ngan S., Seckl M.J., Gestational trophoblastic neoplasia management: an update, Curr Opin Oncol, 19, 5, pp. 486-491, (2007)
  • [5] Fisher R.A., Lawler S.D., Povey S., Bagshawe K.D., Genetically homozygous choriocarcinoma following pregnancy with hydatidiform mole, Br J Cancer, 58, pp. 788-892, (1988)
  • [6] Seckl M.J., Fisher R.A., Salerno G.A., Rees H., Paradinas F.J., Foskett M., Et al., Choriocarcinoma and partial hydatidiform moles, Lancet, 356, pp. 36-39, (2000)
  • [7] Schmid P., Nagai Y., Agarwal R., Hancock B., Savage P.M., Sebire N.J., Et al., Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study, Lancet, 374, 9683, pp. 48-55, (2009)
  • [8] Fisher R.A., Lavery S.A., Carby A., Abu-Hayyeh S., Swingler R., Sebire N.J., Et al., What a difference an egg makes, Lancet, 378, 9807, (2011)
  • [9] Murdoch S., Djuric U., Mazhar B., Seoud M., Khan R., Kuick R., Et al., Mutations in NALP7 cause recurrent hydatidiform moles and reproductive wastage in humans, Nat Genet, 38, 3, pp. 300-302, (2006)
  • [10] Seckl M.J., Sebire N.J., Fisher R.A., Golfier F., Massuger L., Sessa C., Et al., Gestational trophoblastic disease: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 24, pp. vi39-vi50, (2013)
12345